Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Connected Government
- Consolidating Mission-critical Systems
- Constituent Servicing
- Continuous Monitoring: Tools and Techniques for Trustworthy Government IT
- The Data Privacy Imperative: Safeguarding Sensitive Data
- Eliminating the Pitfalls: Steps to Virtualization in Government
- Federal Executive Forum
- Federal Tech Talk
- Government Cloud Brokerage: Who, What, When, Where, Why?
- Government Mobility
- Mission-critical Apps in the Cloud
- Mobile Device Management
- The Modern Federal Threat Landscape
- The Path from Legacy Systems
- Understanding the Intersection of Customer Service and Security in the Cloud
Shows & Panels
Breast cancer drug on the FDA chopping block
Monday - 6/20/2011, 12:17pm EDT
Kathy Stewart, wtop.com
WASHINGTON -- The battle over a breast cancer drug will be heating up at the end of the month after the Federal Drug Administration banned its use.
In 2008, Avastin -- typically taken to treat kidney and colon cancer -- had been fast-tracked to also treat breast cancer. But after the drug's maker, Genentech, completed its third clinical trial, the FDA decided to pull the plug.
Dr. Frederick Tucker, a Fredericksburg oncologist, says the drug simply did not work.
He says the best Genentech could claim is that "Avastin didn't make patients worse." It also did not help them live longer or better while taking the medication.
If Genentech fails to reverse the FDA's decision, the company could lose between $500 million and $1 billion, says Tucker.
A new round of hearings is set for June 28 and 29.
Avastin has already been banned in England for breast cancer patients.
WTOP's Kathy Stewart contributed to this report. Follow WTOP on Twitter.
(Copyright 2011 by WTOP. All Rights Reserved.)